Established benefits of the lipid modulating agents, hydroxymethylglutaryl-CoA reductase (HMGCR) inhibitors, better known as statins, have been demonstrated in the setting of experimental diabetic nephropathy (Bruder-Nascimento et al., 2016; Kim et al., 2016). This evidence concerns the gene HMGCR and diabetic kidney disease.